PA-BOOMI
Boomi™ , the intelligent connectivity and automation leader, today announced the appointment of Madeline Ling as chief financial officer (CFO), Marcy Campbell as chief revenue officer (CRO), and Fran Wilson as chief marketing officer (CMO), effective immediately. Additionally, Emmy award-winning news journalist Christa Delcamp joins Boomi to support public relations and media strategy, and James Dyson joins the company to lead Global Diversity, Equity, and Inclusion Talent Acquisition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005227/en/
“Boomi's recent launch as a standalone company – coupled with our high growth and cutting-edge, cloud-based technology – provides the opportunity to build our leadership team as part of a much larger expansion, with several hundred new hires coming onboard this year,” said David Meredith, CEO at Boomi. “Our industry-leading platform and award-winning culture enabled us to recruit top, globally-minded talent, with a demonstrated track-record of achievement, and a passion to accelerate our mission to make the world a better place by connecting everyone to everything, anywhere.”
The new leadership appointments come after Boomi's recent independence backed by premier private equity firms, Francisco Partners and TPG, in a $4 billion transaction. As a global software as a service (SaaS) category leader with more than 20,000 customers – Boomi touts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSI) in the iPaaS space, which includes Accenture, Deloitte, SAP, and Snowflake, as well as the three largest cloud providers, Amazon Web Services, Google, and Microsoft, among others.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for enterprise platform as a service (EiPaaS)1 for eight consecutive years . The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces . As the company continues to scale rapidly to meet global, enterprise demand for digital connectivity, integration, and automation, Boomi plans to hire several hundred new team members this year to accelerate all functions of the business.
BOOMI ATTRACTS WORLD-CLASS TALENT:
Madeline Ling, CFO
Ling holds a MBA from Stanford Graduate School of Business, and brings nearly 25 years of experience leading equity-backed, global enterprise organizations through strategic and international growth. She has held multiple CFO roles throughout her career, including international assignments overseas. Ling most recently served as corporate CFO for a Hellman and Friedman (H&F) PE-backed portfolio company, and held previous roles at VMware, The Boston Consulting Group, and Intel.
Marcy Campbell, CRO
Campbell brings to Boomi over 30 years of experience leading large-scale, go-to-market organizations for global companies ranging from Fortune 500 to venture-backed technology firms. She most recently served as senior vice president at PayPal where she led global sales, professional services, and operations. At Boomi, Campbell will spearhead the company’s revenue-generating strategies with a focus on driving fast growth, while continuing to deliver customer value.
Fran Wilson, CMO
With more than 20 years of successful experience in SaaS and B2B enterprise software organizations, Wilson provided marketing leadership through Red Hat’s initial public offering (IPO), and during its rapid revenue growth from $400 million to more than $4 billion, culminating in its sale to IBM for $34 billion.
Christa Delcamp, Public Relations and Media Strategy
Delcamp brings over two decades of experience in public relations, journalism, content creation, and communications, across a variety of platforms, including digital/social, NBC and CBS-owned and operated stations, radio/podcasting, and print. An Emmy award-winning news journalist, Delcamp’s extensive expertise in telling impactful stories will help Boomi increase market awareness of its industry-leading platform and important mission to connect the world.
James Dyson, Global Diversity, Equity, and Inclusion (DE&I) Talent Acquisition
Dyson brings over 20 years of experience leading and managing talent acquisition at global companies, including Accenture. In his role, Dyson will leverage his deep expertise and extensive international network to support Boomi’s rapid growth and continue to build the company’s award-winning culture.
Additional Resources
- Check out open roles at Boomi
- Learn more about the Boomi AtomSphere Platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter , LinkedIn , Facebook , and YouTube
Gartner Disclaimer:
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com .
© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
________________________
1
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005227/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom